Condition: Phelan-McDermid Syndrome · Sponsor: Neuren Pharmaceuticals Limited
This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.
This description comes directly from the study's public registry record.
Medical Information Lead · 231-203-8050 · medicalinformation@neurenpharma.com
Always discuss trial participation with your own doctor first.
| Neuren PMS-302 Site#111 | San Rafael, California, United States | Recruiting |
| Neuren PMS-302 Site#109 | Chevy Chase, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07593391